WallStreetZenWallStreetZen

NASDAQ: CARA
Cara Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CARA past revenue growth

How has CARA's revenue growth performed historically?
Company
-49.92%
Industry
148.64%
Market
17.33%
CARA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CARA's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CARA's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CARA earnings and revenue history

Current Revenue
$21.0M
Current Earnings
-$118.5M
Current Profit Margin
-565.2%

CARA Return on Equity

Current Company
-122.1%
Current Industry
-63.5%
Current Market
188%
CARA's Return on Equity (-122.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CARA announces earnings.

CARA Return on Assets

Current Company
-89.6%
Current Industry
2.9%
CARA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CARA Return on Capital Employed

Current Company
-117.61%
Current Industry
19.5%
CARA's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CARA vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CARA$20.97M-$115.58M-$118.51M+9.26%N/A
PMN$0.00-$12.99M-$13.21MN/AN/A
ICCC$17.47M-$3.05M-$5.77M+9.72%N/A
OCUP$19.05M-$9.97M-$9.99M+468.69%N/A
MTNB$1.10M-$22.00M-$22.94M+476.30%N/A
View Top Biotech Stocks

CARA earnings dates

Next earnings date
May 13, 2024

Cara Therapeutics Earnings & Revenue FAQ

What were CARA's earnings last quarter?

On Invalid Date, Cara Therapeutics (NASDAQ: CARA) reported Q4 2023 earnings per share (EPS) of -$0.60, up 7.14% year over year. Total Cara Therapeutics earnings for the quarter were -$32.34 million. In the same quarter last year, Cara Therapeutics's earnings per share (EPS) was -$0.56.

If you're new to stock investing, here's how to buy Cara Therapeutics stock.

What was CARA's earnings growth in the past year?

As of Q2 2024, Cara Therapeutics's earnings has grown year over year. Cara Therapeutics's earnings in the past year totalled -$118.51 million.

What is CARA's earnings date?

Cara Therapeutics's earnings date is Invalid Date. Add CARA to your watchlist to be reminded of CARA's next earnings announcement.

What was CARA's revenue last quarter?

On Invalid Date, Cara Therapeutics (NASDAQ: CARA) reported Q4 2023 revenue of $3.00 million up 7.88% year over year. In the same quarter last year, Cara Therapeutics's revenue was $3.26 million.

What was CARA's revenue growth in the past year?

As of Q2 2024, Cara Therapeutics's revenue has grown -49.92% year over year. This is 198.55 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Cara Therapeutics's revenue in the past year totalled $20.97 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.